Zacks Reiterates “Outperform” Rating for BIO-LIGHT ISRAELI (BLGTY)
September 30th, 2014
BIO-LIGHT ISRAELI logoZacks restated their outperform rating on shares of BIO-LIGHT ISRAELI (NASDAQ:BLGTY) in a report released on Tuesday. Zacks currently has a $14.00 price objective on the stock.
Zacks’ analyst wrote, “BioLight Israeli Life Sciences invests in, manages and commercializes biomedical innovations in the field of ophthalmology and cancer diagnostics. The company offers a rich portfolio of products, of which, IOPtiMate , laser surgical device for glaucoma and CellDetect cell staining technology for detecting and monitoring cancer cells, had a soft launch at the beginning of this year BioLight’s products address a large untapped market which provides an attractive investment opportunity. We initiate coverage on BioLight with an outperform rating.”
